You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Modular antibody engineering to overcome the blood brain barrier

    SBC: ABZYME THERAPEUTICS LLC            Topic: 105

    Abstract Immunotherapy is one of the most promising approaches for treatment of various human diseases including cancers autoimmune and infectious diseases However systemic immunotherapies have been ineffective for central nervous system CNS disorders because the blood brain barrier BBB limits their delivery to the brain Development of new antibody agents able to overcome the BBB is a new ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Cellular Immunotherapy for SSc

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Innovation Corp Program and Commercialization Planning for 'Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone'

    SBC: ACTUATED MEDICAL, INC.            Topic: NCI

    Abstract Project Summary This proposed supplement expands the commercialization and market assessment activities for the original Phase I grant through the Innovation CORPs Program at NIHThe expected primary benefit from I Corps is having dedicated time and mentored direction towards relevant interviews in the endoscopic spacethis is expected to provide invaluable information about the needsin dep ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Ultra High Content Analysis UHCA of Single Cells in Tissue channel immunofluorescence labeling kits and companion imaging software for everyone

    SBC: QUANTITATIVE IMAGING SYSTEMS LLC            Topic: 102

    We propose to create a modular suite of products that will make highly multiplexed imaging of individual cells in intact tissue available to a wide range of laboratories through validated labeling kits and companion imaging software that promotes discovery through interactive image and data visualization Our goal is to create a suite of integrated labeling display and analysis products to elucid ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing and calibrating anisotropic diffusion MR imaging brain connectome with Taxon brain network diffusion phantoms

    SBC: Psychology Software Tools, Inc.            Topic: 105

    This project will provide the first ground truth connection anisotropic diffusion phantom to reproduce human white matter using axon scale diffusion tubes and track micron scale fascicle bundles of axons with a common path The phantom will advance MR diffusion imaging providing accurate calibration quality assurance and research advancement It utilizes innovations in textile engineering ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    SBC: EPIVAX, INC.            Topic: 200

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Biodegradable gold nanoparticles as contrast agents for CT

    SBC: PolyAurum LLC            Topic: NIBIB

    PROJECT SUMMARY Computed tomography is used in about million imaging studies per year in the USA Iodinated contrast agents are used in roughly half of these studies Computed tomography is particularly important for the diagnosis of coronary artery disease where it depends on the use of iodinated contrast agents to visualize the arteries However these agents have a number of shortcomings s ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Small molecule ubiquitin ligase modulators for immunotherapy of cancer

    SBC: PROGENRA INC            Topic: 102

    Abstract An exciting and promising new avenue for cancer treatment is the inhibition of immune evasion the employment by tumors of various strategies to suppress the host immune system s ability to recognize and destroy cancer cells Immunotherapies including monoclonal antibodies transplanted stem cells and engineered T cells vaccines cytokines and T cell checkpoint blockers have shown ef ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Efficacy Evaluation of First in class Imipridone ONC in Recurrent Type II Endometrial Cancer

    SBC: Oncoceutics, Inc.            Topic: 102

    Project Summary ONC is a selective antagonist of the G protein coupled receptor GPCR dopamine receptor domain DRD that is overexpressed in endometrial cancer EC due to its p independent control of the Akt ERK signaling pathways ONC is a first in class small molecule exhibits anticancer efficacy in a wide range of refractory cancers including p mutant cells by simultaneously i ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government